Alpharma Asks Appeals Court To Remove Stay On Neurontin Capsule Launch

Law360, New York (September 13, 2004, 12:00 AM EDT) -- Generics maker Alpharma Inc. has asked an appeals court to lift its order to stay the U.S. Food and Drug Administration’s final approval of the company’s generic version of Pfizer's epilepsy treatment Neurontin.

If the stay is lifted, Alpharma plans to commence commercial sales of gabapentin capsules, the generic name of Neurontin, the company said in a statement.

Alpharma’s plans to start the commercial sales of gabapentin capsules are not contingent on the conclusion of the ongoing patent infringement case with Pfizer, according to the generics...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.